Skip to main navigation

Skip to Content

Overview
News & Events
- News Releases
- Events & Presentations
Governance
Stock Information
Financials
- SEC Filings
Resources

News Releases

Year

Apr 18, 2023

Tango Therapeutics Presents Preclinical Data on Precision Oncology Programs at the American Association of Cancer Research 2023 Annual Meeting

Apr 03, 2023

Tango Therapeutics Announces FDA Clearance of Investigational New Drug Application for TNG260, a First-in-Class CoREST Inhibitor for the Treatment of STK11-Mutant Cancers

Mar 27, 2023

Tango Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Highlights

Mar 14, 2023

Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Programs at the American Association of Cancer Research 2023 Annual Meeting

Mar 10, 2023

Tango Therapeutics Announces Limited Exposure to Silicon Valley Bank

Mar 06, 2023

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 01, 2023

Tango Therapeutics to Participate in Upcoming Investor Conferences

Feb 28, 2023

Tango Therapeutics Announces Appointment of Adam Crystal, M.D., Ph.D. as President of Research and Development

Feb 02, 2023

Tango Therapeutics to Participate in Upcoming Investor Conferences

Jan 25, 2023

Tango Therapeutics Announces FDA Clearance of Investigational New Drug Application for TNG462; Provides Additional Business Updates

Pagination

First page
Previous page
Page 1
Current page 2

Displaying 11 - 20 of 20

Print

RSS Feeds

Email Alerts

Contact IR

Tango Therapeutics, Inc
201 Brookline Avenue, Suite 901
Boston, Massachusetts 02215
Tel: +1-857-320-4900

contact | careers |